Figure 7.

Effect of multiple dosing. (A) Fitness values, F, for treatment regimens comprising a first dosing at 48h with a dose, D₁, ranging between 1 and 11 mg/kg, and a second dosing at time ranging between 96 and 504h, with a dose of 12 mg/kg - D₁. (B) Model simulations of the three populations of interest: neutrophils (dashed lines), lymphocytes (dash-dot) and pathogen(continuous), under continuous treatment with meropenem (antibiotics), 70 mg/L, i.v. application, administered at t=0, and nivolumab, 12 mg/kg, administered in two doses of 6 mg/kg, with administration times as follows: 24h and 168h (top), 48h and 240h (middle), 24h and 336h (bottom). For equations see Methods section. For parameter values, see legend to Figure 3A and Table 1.